- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07561840
Exercise Training After Upper Gastrointestinal Cancer Surgery
May 15, 2026 updated by: Takuya Fukushima, Kansai Medical University
Exercise and Cardiorespiratory Fitness Improvement Through Supervised Training in Upper Gastrointestinal Cancer Surgery Patients (EXCITING-UGI)
This randomized controlled trial aims to determine the optimal exercise intensity for improving postoperative recovery in patients with upper gastrointestinal cancer.
Participants who have undergone curative surgery will be randomly assigned to high-intensity interval training (HIIT), low-intensity continuous training (LICT), or usual care.
The exercise interventions will be performed under supervision three times per week for eight weeks.
The primary outcome is peak oxygen uptake (VO₂peak), assessed using cardiopulmonary exercise testing.
Secondary outcomes include physical function, body composition, patient-reported outcomes, and biological and mechanistic markers such as inflammatory biomarkers, muscle-related factors, and gut microbiota.
This study will also explore potential mechanisms underlying exercise-induced adaptations and their association with clinical outcomes.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This study is a single-center, three-arm randomized controlled trial designed to evaluate the effects of exercise intensity on postoperative recovery in patients with upper gastrointestinal cancer.
Patients who have undergone curative surgery for esophageal or gastric cancer will be enrolled 6 ± 2 weeks after surgery and randomly assigned to high-intensity interval training (HIIT), low-intensity continuous training (LICT), or usual care.
The exercise intervention consists of supervised aerobic and resistance training performed three times per week for eight weeks.
HIIT involves repeated high-intensity intervals interspersed with recovery periods, whereas LICT consists of continuous low-intensity aerobic exercise.
The primary outcome is the change in peak oxygen uptake (VO₂peak) from baseline to 8 weeks, assessed using cardiopulmonary exercise testing.
Secondary outcomes include measures of physical function, skeletal muscle mass, physical activity, quality of life, and biological and mechanistic outcomes such as inflammatory biomarkers, muscle-related factors, and gut microbiome composition.
This study aims to clarify the dose-response relationship of exercise intensity and to explore the physiological mechanisms underlying exercise-induced adaptations in the early postoperative phase.
Study Type
Interventional
Enrollment (Estimated)
171
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Takuya Fukushima
- Phone Number: +81-72-856-2115
- Email: fukushima.tky@kmu.ac.jp
Study Contact Backup
- Name: Jiro Nakano
- Phone Number: +81-72-856-2115
- Email: nakano.jir@kmu.ac.jp
Study Locations
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1136
- Not yet recruiting
- Kansai Medical University
-
Contact:
- Takuya Fukushima
- Phone Number: +81-72-856-2115
- Email: fukushima.tky@kmu.ac.jp
-
Contact:
- Jiro Nakano
- Phone Number: +81-72-856-2115
- Email: nakano.jir@kmu.ac.jp
-
Principal Investigator:
- Takuya Fukushima
-
Hirakata, Osaka, Japan, 573-1136
- Recruiting
- Kansai Medical University
-
Contact:
- Takuya Fukushima
- Phone Number: +81-72-856-2115
- Email: fukushima.tky@kmu.ac.jp
-
Contact:
- Jiro Nakano
- Phone Number: +81-72-856-2115
- Email: nakano.jir@kmu.ac.jp
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosed with esophageal or gastric cancer
- Received curative surgery
- 6 ± 2 weeks after surgery
- Ability to provide written informed consent
Exclusion Criteria:
- Communication difficulties
- Poor general status
- Undergone combined laryngopharyngectomy
- Unsuitable for evaluation or exercise intervention
- Unsuitable for the study as determined by the primary physician
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High-Intensity Interval Training (HIIT)
Participants will perform supervised aerobic high-intensity interval training combined with resistance training.
Aerobic training is performed on a cycle ergometer and consists of four sets of 4-minute work intervals at 80-95% of VO₂peak, interspersed with 3-minute recovery intervals at 60% of VO₂peak.
Each session includes a 3-minute warm-up and a 3-minute cool-down, for a total duration of 34 minutes per session.
Exercise is performed three times per week for eight weeks.
Resistance training includes chest press, leg extension, leg press, and abdominal exercises using pneumatic resistance machines (HUR, Finland), consisting of two sets of 20-25 repetitions at approximately 20RM.
Nutritional counseling is provided by a registered dietitian once every four weeks for a total of two sessions during the intervention period.
|
Supervised aerobic high-intensity interval training combined with resistance training and nutritional counseling.
Aerobic training is performed on a cycle ergometer and consists of four sets of 4-minute high-intensity intervals at 80-95% of VO₂peak, interspersed with 3-minute recovery periods at 60% of VO₂peak.
Each session includes a 3-minute warm-up and a 3-minute cool-down, with a total duration of 34 minutes.
Training is performed three times per week for eight weeks.
Resistance training includes chest press, leg extension, leg press, and abdominal exercises using pneumatic resistance machines, consisting of two sets of 20-25 repetitions at approximately 20RM.
Nutritional counseling is provided by a registered dietitian once every four weeks for a total of two sessions during the intervention period.
Other Names:
|
|
Experimental: Low-Intensity Continuous Training (LICT)
Participants will perform supervised low-intensity continuous training combined with resistance training and nutritional counseling.
Aerobic training is performed on a cycle ergometer at 37-45% of VO₂peak for 28 minutes per session, with a 3-minute warm-up and a 3-minute cool-down, for a total duration of 34 minutes.
Exercise is performed three times per week for eight weeks.
Resistance training includes chest press, leg extension, leg press, and abdominal exercises using pneumatic resistance machines (HUR, Finland), consisting of two sets of 20-25 repetitions at approximately 20RM.
Nutritional counseling is provided by a registered dietitian once every four weeks for a total of two sessions during the intervention period.
|
Supervised low-intensity continuous training combined with resistance training and nutritional counseling.
Aerobic training is performed on a cycle ergometer at 37-45% of VO₂peak for 28 minutes per session, with a 3-minute warm-up and a 3-minute cool-down, for a total duration of 34 minutes.
Training is performed three times per week for eight weeks.
Resistance training is identical to the HIIT group and includes chest press, leg extension, leg press, and abdominal exercises using pneumatic resistance machines, consisting of two sets of 20-25 repetitions at approximately 20RM.
Nutritional counseling is provided by a registered dietitian once every four weeks for a total of two sessions during the intervention period.
Other Names:
|
|
No Intervention: Usual Care (Control)
Participants will receive usual postoperative care without structured exercise intervention.
Nutritional counseling is provided by a registered dietitian once every four weeks for a total of two sessions during the study period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak oxygen uptake (VO₂peak)
Time Frame: Baseline and 8 weeks after the intervention
|
Cardiorespiratory fitness will be assessed using symptom-limited cardiopulmonary exercise testing (CPET) on a cycle ergometer under medical supervision with continuous breath-by-breath gas analysis.
After a 4-minute unloaded warm-up, workload is increased by 10-20 W/min depending on patient condition, with participants cycling at 50 rpm until volitional exhaustion.
The test is terminated when cadence falls below 40 rpm, at physician discretion, or at patient exhaustion, followed by a 2-minute cool-down at 20 W. Continuous 12-lead ECG, blood pressure, and oxygen saturation are monitored during testing.
VO₂peak is defined as the highest 30-second averaged oxygen uptake immediately prior to exhaustion.
Peak workload, peak heart rate, and oxygen uptake at ventilatory threshold are also recorded.
|
Baseline and 8 weeks after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Handgrip strength
Time Frame: Baseline and 8 weeks after the intervention
|
Handgrip strength will be measured using a standard adjustable-handle dynamometer (InGrip, InBody Japan Inc., Tokyo, Japan).
Measurements will be performed in a standing position with arms at the side.
Two maximal voluntary efforts will be recorded for each hand, and the highest value will be used (kg) as the outcome measure.
|
Baseline and 8 weeks after the intervention
|
|
Chair stand test
Time Frame: Baseline and 8 weeks after the intervention
|
Lower-limb muscle strength will be assessed using the 30-second chair stand test (CS-30).
Participants will perform as many sit-to-stand repetitions as possible within 30 seconds without using their hands from a standard chair (approximately 43 cm seat height).
The total number of completed stands will be recorded.
Extended versions (CS-60 and CS-90) will be derived as endurance indicators.
|
Baseline and 8 weeks after the intervention
|
|
Short Physical Performance Battery (SPPB)
Time Frame: Baseline and 8 weeks after the intervention
|
Physical performance will be assessed using the SPPB, consisting of standing balance, gait speed, and chair stand tests.
Each component is scored and summed to produce a total score ranging from 0 (worst performance) to 12 (best performance).
|
Baseline and 8 weeks after the intervention
|
|
Skeletal muscle mass
Time Frame: Baseline and 8 weeks after the intervention
|
Skeletal muscle mass will be measured using a segmental multi-frequency bioelectrical impedance analyzer (InBody770, InBody Japan Inc., Tokyo, Japan).
|
Baseline and 8 weeks after the intervention
|
|
Total exercise volume
Time Frame: During the 8-week intervention period
|
Total exercise volume will be calculated as the cumulative prescribed aerobic and resistance exercise over the 8-week intervention period.
Aerobic exercise volume will be based on prescribed duration and intensity (HIIT or LICT protocols).
Resistance training volume will be calculated by taking into account both the number of sets and repetitions performed across all prescribed exercises during the intervention period.
|
During the 8-week intervention period
|
|
Exercise adherence
Time Frame: During the 8-week intervention period
|
Exercise adherence will be defined as the proportion of completed supervised exercise sessions and compliance with the prescribed exercise protocol, expressed as a percentage.
|
During the 8-week intervention period
|
|
Patient-reported outcomes
Time Frame: Baseline and 8 weeks after the intervention
|
Health-related quality of life and symptoms will be assessed using the EORTC QLQ-C30.
Scores for functional scales, symptom scales, and global health status will be linearly transformed to a 0-100 scale.
|
Baseline and 8 weeks after the intervention
|
|
Blood biomarkers
Time Frame: Baseline and 8 weeks after the intervention
|
Serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), irisin, SPARC, and adrenaline will be measured.
|
Baseline and 8 weeks after the intervention
|
|
Gut microbiome
Time Frame: Baseline and 8 weeks after the intervention
|
Gut microbiome composition will be analyzed using 16S rRNA sequencing of stool samples to assess alpha diversity, beta diversity, and taxonomic composition.
|
Baseline and 8 weeks after the intervention
|
|
Urinary urea nitrogen
Time Frame: Baseline and 8 weeks after the intervention
|
Urinary urea nitrogen (UUN) as an indicator of protein metabolism and nutritional status.
|
Baseline and 8 weeks after the intervention
|
|
Adverse events
Time Frame: During the 8-week intervention period
|
All adverse events will be systematically recorded throughout the study period.
|
During the 8-week intervention period
|
|
Pneumonia
Time Frame: During the 8-week intervention period
|
Pneumonia will be defined as new or progressive infiltrates on chest radiographs or CT scans, as well as meeting at least two of the following three criteria: body temperature greater than 38°C, leukopenia or leukocytosis (white blood cell count less than 4 × 10⁹/L or greater than 10 × 10⁹/L), and purulent sputum.
|
During the 8-week intervention period
|
|
Readmission
Time Frame: During the 8-week intervention period
|
Unplanned hospital readmission will be defined as any admission occurring after discharge and within the study period, extracted from medical records.
|
During the 8-week intervention period
|
|
Physical activity (Japanese version of the International Physical Activity Questionnaire-Short Form)
Time Frame: Baseline and 8 weeks after the intervention
|
Physical activity will be assessed using the Japanese version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF).
The IPAQ-SF provides an estimate of total physical activity expressed in metabolic equivalent task minutes per week (MET-min/week), calculated based on walking, moderate, and vigorous physical activities.
The total score ranges from 0 to theoretically unlimited values, with higher scores indicating greater levels of physical activity.
|
Baseline and 8 weeks after the intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Takuya Fukushima, Kansai Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 15, 2026
Primary Completion (Estimated)
November 1, 2029
Study Completion (Estimated)
November 1, 2029
Study Registration Dates
First Submitted
April 24, 2026
First Submitted That Met QC Criteria
April 24, 2026
First Posted (Actual)
May 1, 2026
Study Record Updates
Last Update Posted (Actual)
May 19, 2026
Last Update Submitted That Met QC Criteria
May 15, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Pathological Conditions, Signs and Symptoms
- Behavior
- Stomach Neoplasms
- Esophageal Neoplasms
- Disease
- Gastrointestinal Neoplasms
- Motor Activity
- Motor Activity
- Movement
- Musculoskeletal Physiological Phenomena
- Musculoskeletal and Neural Physiological Phenomena
- Physical Conditioning, Human
- Exercise
- High-Intensity Interval Training
Other Study ID Numbers
- 2025287
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data will not be shared due to ethical considerations and the sensitive nature of clinical and biological data collected from patients with cancer.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
National Cancer Institute (NCI)NRG OncologyCompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7United States
-
Essen BiotechRecruitingStomach Cancer | Esophageal Cancer | Stomach Cancer, Adenocarcinoma | Stomach Cancer Recurrent | Esophageal Cancer Metastatic to Bone | Esophageal Cancer Metastatic to Lung | Esophageal Cancer Metastatic to LiverChina
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
University of Wisconsin, MadisonCompletedResectable Esophageal Cancer | GastroEsophageal CancerUnited States
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7 | Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm...United States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
Clinical Trials on High-Intensity Interval Training (HIIT)
-
Université de SherbrookeRecruiting
-
Wroclaw University of Health and Sport SciencesActive, not recruitingPhysical Activity | Blood Pressure | Cardiorespiratory Fitness | Adipose Tissue | AdolescentsPoland
-
Mayo ClinicActive, not recruitingCardiac RehabilitationUnited States
-
Karolinska University HospitalKarolinska InstitutetUnknownDermatomyositis | PolymyositisSweden
-
Wu JiarunCompletedBurnout,Motivation,Stress,Mental ToughnessMalaysia
-
McMaster UniversityCompleted
-
Chang Gung Memorial HospitalCompletedHeart Failure | Morality | Remodeling, VentricularTaiwan
-
Brock UniversityCompletedCardiovascular Diseases | Metabolic SyndromeCanada
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedKnee OsteoarthritisUnited States
-
Amsterdam UMC, location VUmcRecruitingExercise | Brain Tumor, PrimaryNetherlands